Korea (South)noveltynobility.com
Novelty Nobility Inc. is a South Korean biotechnology company focused on the development of bispecific antibody therapeutics. Its lead candidate, NN4101, targets retinal neovascular diseases and is being advanced in collaboration with AGC Biologics. The partnership encompasses cell-line development, master cell bank creation, process optimization, and GMP manufacturing across facilities in Denmark, Japan, the United States, and Europe.
None yet. When a new project in the record names Novelty Nobility as owner, partner or investor, it shows here.
With Novelty Nobility, moves Copenhagen cell‑line/MCB work to GMP manufacturing in Chiba from May 2026. Targets retinal neovascular disease; global cGMP network enables tech transfer.
